Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
418 Leser
Artikel bewerten:
(2)

Ascensia Presents First Ever Data At Australasian Diabetes Conference 2021 Exploring The Profiles Of Australian ContourDiabetes App Users

SYDNEY, Aug. 11, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes company has today disclosed data at the virtual Australasian Diabetes Conference (ADC) 2021, which takes place August 11-13. The two posters presented for the first time data that analysed CONTOURDIABETES App (CDA) usage in Australia in people who measure blood glucose at least once daily with the CONTOURNEXT ONE (CNO) blood glucose monitoring system (BGMS) linked with CDA.

Ascensia Diabetes Care

The first poster[1], 'Baseline characteristics of people in Australia using CONTOURDIABETES Smartphone Applications for the self-management of Diabetes' explores the profiles of people with diabetes who were using the CDA with the CNO BGMS over a three month period. The data showed that more than 60% of the assessed population reported to have Type 2 Diabetes and 40% indicated that they were treated by insulin alone and/or in combination with oral antidiabetic medications. Of greater relevance, this study revealed that more than 50% of them were aged 60 or above.

The second poster[2] 'Dynamics of using CONTOURDIABETES smartphone application for the self-management of Diabetes over a 32 month period in Australia' is the first real-world analysis in Australia to identify any association of gender, age and therapy profile in CDA users over a long term period, between August 1, 2018 and March 30, 2021. The study found a significantly higher percentage of men than women used the CDA. This is also true of users aged 60 years or over. Only 40% reported treatment by insulin therapies alone or in combination with other glucose lowering medications, while others were on diet and exercise alone or used various non-insulin therapies.

Bodil Worm, Country Manager Australia at Ascensia Diabetes Care, commented: "There are some surprising findings that came out of data analysis. Firstly, many would think that the greatest uptake of app usage would be among the younger generation, however, this analysis contradicts that with the majority of the assessed population being aged 60 or over, which indicates that advances in mobile health apps remain relevant and applicable to this age group. Similarly, while one would expect those on insulin therapies to check their blood glucose levels at least once a day, we have also seen those on non-insulin therapies were monitoring their blood glucose regularly, perhaps suggesting that they are interested to know how various factors such as different foods, exercise or medication impact their blood glucose.

Worm continued: "The majority of Australians are using a smartphone[3], however research showed that only 8% of people with Type 2 Diabetes and 24% with Type 1 Diabetes were actually using an app aimed at helping them with their diabetes management[4]. This highlights the disconnect between people having the necessary technology to adopt digital solutions to support the self-management of their diabetes and their decision to do so. We believe there is an opportunity for all stakeholders in the healthcare arena to recommend the use of apps as an adjunct to current diabetes tools. Even more so during the COVID pandemic, where attending face-to-face appointments is becoming more difficult, the apps provide an avenue to share data remotely in order to make more informed decisions and to optimize treatment and care plans."

[1] Mak,W., Pardo, S., Shaginian,R., Baseline characteristics of people in Australia using CONTOURDIABETES Smartphone Application for the self-management of Diabetes - Poster presented at the Australasian Diabetes Congress 2021.

[2] Mak,W., Pardo, S., Shaginian,R., Dynamics of using CONTOURDIABETES smartphone application for the self-management of Diabetes over 32 months period in Australia. Poster presented at the Australasian Diabetes Congress 2021.

[3] Deloitte. Digital Consumer Trends 2020: Australian edition.

[4] Trawley S et al. (2017) The Use of Mobile Applications among adults with Type 1 and Type 2 Diabetes: Results from the Second Miles Australia(MILES-2) study Diabetes Technol Ther.;19(12):730-8.

Logo- https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.